Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
13 p, 861.9 KB Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial / Dimopoulos, M. A. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens. School of Medicine) ; Špička, I. (First Department of Medicine. Department of Hematology. First Faculty of Medicine. Charles University. General Hospital in Prague) ; Quach, H. (St Vincent's Hospital (Sydney)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ; Garg, M. (Leicester General Hospital (Leicester, Regne Unit)) ; Beksac, M. (Department of Hematology. Ankara University) ; Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ; Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ; Chng, W. J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ; Leleu, X. (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ; Mateos, M. V. (Hospital Universitario de Salamanca. Centro de Investigación del Cáncer) ; Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ; Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ; Universitat Autònoma de Barcelona
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041  
2.
8 p, 788.7 KB A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) / Hájek, R. (University Hospital Ostrava) ; Masszi, T. (St László Hospital (Hongria)) ; Petrucci, M. T. (Sapienza Università di Roma) ; Palumbo, A. (Università di Torino) ; Rosiñol, L. (Hospital Clínic i Provincial de Barcelona) ; Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ; Yong, K. L. (University College London Cancer Institute) ; Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Minarik, J. (University Hospital Olomouc (Olomouc, República Txeca)) ; Pour, L. (University Hospital Ostrava) ; Dimopoulos, M. A. (National and Kapodistrian University of Athens) ; Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ; Rossi, Davide (Amedeo Avogadro University of Eastern Piedmont) ; Kasparu, H. (Hospital Elisabethinen Linz) ; Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ; Yehuda, D. B. (Hadassah Medical Center, Jerusalem, Israel) ; Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ; Jenner, M. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ; Dávid, M. (University of Pécs, Hungary) ; de la Rubia, J. (Hospital Universitari i Politècnic La Fe de València) ; Drach, J. (Medical University of Vienna) ; Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ; Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ; Leleu, X. (Hopital Huriez, CHRU, Lille, France) ; Munder, M. (University Medicine Mainz, Germany) ; Offidani, M. (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ; Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ; Rajangam, K. (Onyx Pharmaceuticals, Inc.) ; Chang, Y. L. (Onyx Pharmaceuticals, Inc.) ; San-Miguel, J. F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114  

Vea también: autores con nombres similares
4 Dimopoulos, M.
2 Dimopoulos, M. A.
1 Dimopoulos, MA
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.